Laurus Labs Limited
Mirae Asset Mutual Fund decreased its stake in Laurus Labs Limited from 4.47% to 4.33% by reducing its shareholding from 24,110,341 to 23,387,661 shares.
A research-driven pharmaceutical and biotechnology company specializing in Active Pharmaceutical Ingredients for anti-retroviral, oncology, cardiovascular, and gastroenterology therapies with global leadership positions in select segments. Laurus Labs operates multiple facilities approved by major regulatory agencies including USFDA, WHO-Geneva, EMA, and others. The company provides integrated contract manufacturing and development services to international pharmaceutical innovators across clinical development through commercial production stages.
Indian arm of South Korea's Mirae Asset Global Investments, one of Asia's largest asset managers. Manages over Rs 2.5 lakh crore in India across equity and hybrid funds. CIO Neelesh Surana has built a reputation for rigorous bottom-up stock selection with a long-term quality growth bias. Mirae Asset Emerging Bluechip Fund built a cult following before being closed to fresh investments due to size.